Discovery and\nPreclinical Profile of ALG-055009, a\nPotent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist\nfor the Treatment of MASH

Agonists of thyroid hormone receptor\nβ (THR-β)\ndecreased\nLDL cholesterol (LDL-C) and triglyceride (TG) levels in human clinical\ntrials for patients with dyslipidemia. The authors present the highly\npotent and selective compound ALG-055009 (<b>14</b>) as a potential\nbest in class THR-β agonist. The high metabolic stability and\ngood permeability translated well in vivo to afford a long in vivo\nhalf-life pharmacokinetic profile with limited liability for DDI,\nand it overcomes certain drawbacks seen in recent clinical candidates.